{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=100",
    "query": {
      "intervention": "Continuous Dose",
      "page": 100
    },
    "page_size": 10
  },
  "pagination": {
    "page": 100,
    "page_size": 10,
    "total_count": 5326,
    "total_pages": 533,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=101&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=99&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T06:30:59.008Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01943799",
      "title": "Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic HBV Infection"
      ],
      "interventions": [
        {
          "name": "GS-4774",
          "type": "BIOLOGICAL"
        },
        {
          "name": "OAV Regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 178,
      "start_date": "2013-09-13",
      "completion_date": "2015-03-03",
      "has_results": true,
      "last_update_posted_date": "2019-11-01",
      "last_synced_at": "2026-11-15T06:30:59.008Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Pasadena, California • Sacramento, California + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01943799"
    },
    {
      "nct_id": "NCT01469052",
      "title": "First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "AG-013736",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2002-11",
      "completion_date": "2004-08",
      "has_results": true,
      "last_update_posted_date": "2012-03-26",
      "last_synced_at": "2026-11-15T06:30:59.008Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Houston, Texas • Madison, Wisconsin",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01469052"
    },
    {
      "nct_id": "NCT07283848",
      "title": "Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma Stomach",
        "Adenocarcinoma Gastroesophageal Junction"
      ],
      "interventions": [
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Domvanalimab",
          "type": "DRUG"
        },
        {
          "name": "FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2026-02-01",
      "completion_date": "2029-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-11-15T06:30:59.008Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07283848"
    },
    {
      "nct_id": "NCT05614115",
      "title": "Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End-stage Kidney Disease",
        "Kidney Disease, Chronic",
        "Dialysis",
        "Diabetic",
        "Non-diabetic",
        "Kidney Dysfunction",
        "Kidney Failure",
        "Hemodialysis"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2023-03-21",
      "completion_date": "2025-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-15T06:30:59.008Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05614115"
    },
    {
      "nct_id": "NCT01947699",
      "title": "Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Gestational Diabetes"
      ],
      "interventions": [
        {
          "name": "Glyburide",
          "type": "DRUG"
        },
        {
          "name": "Continuous glucose monitor",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2013-09",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2016-05-11",
      "last_synced_at": "2026-11-15T06:30:59.008Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01947699"
    },
    {
      "nct_id": "NCT03435952",
      "title": "Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Neoplasm of Breast",
        "Malignant Neoplasms of Digestive Organs",
        "Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System",
        "Malignant Neoplasms of Female Genital Organs",
        "Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites",
        "Malignant Neoplasms of Independent (Primary) Multiple Sites",
        "Malignant Neoplasms of Lip Oral Cavity and Pharynx",
        "Malignant Neoplasms of Male Genital Organs",
        "Malignant Neoplasms of Mesothelial and Soft Tissue",
        "Malignant Neoplasms of Respiratory and Intrathoracic Organs",
        "Malignant Neoplasms of Thyroid and Other Endocrine Glands",
        "Malignant Neoplasms of Urinary Tract"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Clostridium Novyi-NT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Doxycycline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2018-07-10",
      "completion_date": "2026-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-15T06:30:59.008Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03435952"
    },
    {
      "nct_id": "NCT03785249",
      "title": "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer",
        "Metastatic Cancer",
        "Malignant Neoplastic Disease"
      ],
      "interventions": [
        {
          "name": "MRTX849",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Afatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 731,
      "start_date": "2019-01-15",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-11-15T06:30:59.008Z",
      "location_count": 221,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 156 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03785249"
    },
    {
      "nct_id": "NCT04163458",
      "title": "Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infertility"
      ],
      "interventions": [
        {
          "name": "MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL",
          "type": "DRUG"
        },
        {
          "name": "MENOPUR powder and solvent for solution for injection, 75 IU",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for MENOPUR solution for injection in pre-filled pen)",
          "type": "OTHER"
        },
        {
          "name": "Placebo (for MENOPUR powder and solvent for solution for injection)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "42 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 42 Years · Female only"
      },
      "enrollment_count": 405,
      "start_date": "2019-10-25",
      "completion_date": "2021-07-16",
      "has_results": true,
      "last_update_posted_date": "2023-11-07",
      "last_synced_at": "2026-11-15T06:30:59.008Z",
      "location_count": 20,
      "location_summary": "Tempe, Arizona • San Diego, California • Farmington, Connecticut + 17 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04163458"
    },
    {
      "nct_id": "NCT02891278",
      "title": "Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Sertraline",
          "type": "DRUG"
        },
        {
          "name": "Cytosine arabinoside",
          "type": "DRUG"
        },
        {
          "name": "allogeneic stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 6,
      "start_date": "2016-08-11",
      "completion_date": "2020-11-17",
      "has_results": false,
      "last_update_posted_date": "2023-04-12",
      "last_synced_at": "2026-11-15T06:30:59.008Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • New York, New York",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02891278"
    },
    {
      "nct_id": "NCT04409587",
      "title": "Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mountain Diabetes and Endocrine Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2018-04-12",
      "completion_date": "2020-11-01",
      "has_results": false,
      "last_update_posted_date": "2021-02-24",
      "last_synced_at": "2026-11-15T06:30:59.008Z",
      "location_count": 1,
      "location_summary": "Asheville, North Carolina",
      "locations": [
        {
          "city": "Asheville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04409587"
    }
  ]
}